Globus Medical Inc (NYSE:GMED) has been assigned a consensus recommendation of “Buy” from the fifteen research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $41.50.
A number of brokerages have recently commented on GMED. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $51.00 price target (up from $46.00) on shares of Globus Medical in a research note on Wednesday, January 10th. Barclays reaffirmed a “sell” rating and issued a $36.00 price target on shares of Globus Medical in a research note on Wednesday, January 10th. Zacks Investment Research raised Globus Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Morgan Stanley raised Globus Medical from an “equal weight” rating to an “overweight” rating and set a $48.00 price target for the company in a research note on Tuesday, January 2nd. Finally, BTIG Research set a $45.00 price target on Globus Medical and gave the company a “buy” rating in a research note on Tuesday, January 2nd.
In related news, President Anthony L. Williams sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $38.30, for a total value of $574,500.00. Following the completion of the transaction, the president now directly owns 15,000 shares in the company, valued at approximately $574,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Steven Payne sold 3,076 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $39.30, for a total value of $120,886.80. Following the completion of the transaction, the chief accounting officer now owns 23,847 shares of the company’s stock, valued at $937,187.10. The disclosure for this sale can be found here. Insiders sold a total of 73,459 shares of company stock valued at $2,947,260 over the last quarter. 28.21% of the stock is owned by insiders.
Shares of Globus Medical (GMED) opened at $45.06 on Tuesday. The company has a market capitalization of $4,245.36, a PE ratio of 40.96, a PEG ratio of 2.58 and a beta of 0.48. Globus Medical has a 52 week low of $26.53 and a 52 week high of $47.09.
Globus Medical Company Profile
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.